Jun 24 |
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
|
Jun 17 |
Sellas falls 17% amid Phase 3 study update for galinpepimut-S
|
Jun 17 |
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
|
Jun 10 |
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
|
May 22 |
Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?
|
May 21 |
Solaris Resources announces $35 million bought deal offering
|
May 14 |
SELLAS Life Sciences GAAP EPS of -$0.21
|
May 14 |
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 1 |
Sellas reports positive Phase 2 data from AML study, files for patent
|
May 1 |
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
|